Activist investment fund Starboard Value took at stake in Pfizer recently, hoping to change its course. Starboard claimed that a pair of former top managers were willing to act as advisors.

Pfizer challenges the status quo by introducing us to a new and surprising salutation: "Get old". "We're challenging people of all ages to rethink what it means to get old," reads the campaign's ...

Sept 26 (Reuters) - U.S. drugmaker Pfizer (PFE.N), opens new tab said on Wednesday it was withdrawing its sickle cell disease treatment Oxbryta from all markets where it is approved, citing risks ...

Pfizer PFE stock has risen 7.3% in the past three months compared with an increase of 2.9% for the industry. The stock has also outperformed the sector as well as the S&P 500, as seen in the chart ...

Pfizer PFE3.46%increase; green up pointing triangle said it is voluntarily withdrawing all lots of its sickle-cell drug Oxbryta in all markets where it is approved, two years after acquiring its ...

Board of Directors approves quarterly cash dividend of $0.42 per share NEW YORK, October 09, 2024--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $ ...

Pfizer’s decision Wednesday to pull its sickle cell pill off the market because of safety concerns shocked advocates and doctors, leaving many searching for answers and scrambling for ways to ...

Pfizer will voluntarily pull its sickle cell disease (SCD) drug Oxbryta from all markets worldwide, a major blow to a $5.4 billion acquisition the New York pharma made two years ago. Pfizer will ...

Sept 26 (Reuters) - Pfizer's (PFE.N), opens new tab decision late on Wednesday to withdraw its sickle cell disease treatment due to the risk of death could help speed up trials of new experimental ...

Pfizer (NYSE:PFE) has voluntarily withdrawn all lots of its sickle cell disease drug Oxbryta, also known as voxelotor, over safety concerns. The pharmaceutical giant said Oxbryta will be withdrawn ...